Vimarsana
Biggest News Aggregation in the World

Page 8 - Nasdaq Cccc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Cccc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Cccc Today - Breaking & Trending Today

C4 Therapeutics, Inc. (NASDAQ:CCCC) Expected to Announce Earnings of -$0.61 Per Share - Vimarsana News

C4 Therapeutics, Inc. (NASDAQ:CCCC) Expected to Announce Earnings of -$0.61 Per Share

Brokerages predict that C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) will post earnings per share (EPS) of ($0.61) for the current quarter, according to Zacks. Six analysts have made estimates for C4 Therapeutics’ earnings. The lowest EPS estimate is ($0.64) and the highest is ($0.60). C4 Therapeutics reported earnings of ($0.49) per share during the […]

Bank of America Lowers C4 Therapeutics (NASDAQ:CCCC) to Neutral - Vimarsana News

Bank of America Lowers C4 Therapeutics (NASDAQ:CCCC) to Neutral

Bank of America cut shares of C4 Therapeutics (NASDAQ:CCCC – Get Rating) from a buy rating to a neutral rating in a research note released on Sunday, MarketBeat.com reports. The firm currently has $15.00 price target on the stock, down from their previous price target of $46.00. CCCC has been the topic of several other […]

Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Grows By 29.7% - Vimarsana News

Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Grows By 29.7%

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 4,720,000 shares, an increase of 29.7% from the February 28th total of 3,640,000 shares. Approximately 12.4% of the company’s shares are short sold. Based […]

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $44.88 Consensus PT from Brokerages - Vimarsana News

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $44.88 Consensus PT from Brokerages

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) have earned an average rating of “Buy” from the ten brokerages that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that […]

C4 Therapeutics Appoints Utpal Koppikar to Board of - Vimarsana News

C4 Therapeutics Appoints Utpal Koppikar to Board of

– Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee...